MedTrace Logo

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

NCT07280312 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-03

No results posted yet for this study

Summary

This clinical trial studies how well ultrasound microvessel imaging (UMI) works in evaluating ovarian and adnexal lesions in patients who are scheduled to have surgical treatment for their ovarian or adnexal lesions as part of their clinical care. Ovarian cancer is the most lethal gynecologic malignancy, often diagnosed at an advanced stage. Current diagnostic tools include a blood test (serum cancer antigen 125 \[CA125\]) and transvaginal ultrasound. However, CA125 has limited diagnostic accuracy and is Food and Drug Administration-approved only for monitoring the return of cancer (recurrence), not for preoperative diagnosis. A key measurement in calculating ovarian and adnexal cancer risk is by looking at increased blood flow, which may suggest a higher risk of cancer developing. However, current ultrasound techniques have limited ability to assess blood flow. A new ultrasound technique, UMI, may have higher sensitivity for detecting small blood vessels compared to traditional ultrasound imaging.

Conditions

  • Female Reproductive System Adnexal Neoplasm
  • Ovarian Carcinoma
  • Female Reproductive System Neoplasm
  • Ovarian Neoplasms
  • Adnexal Lesion
  • Ovarian Lesion

Interventions

PROCEDURE

Transvaginal Ultrasound

Undergo transvaginal ultrasound

PROCEDURE

Ultrasound Microvessel Imaging

Undergo UMI

Sponsors & Collaborators

Principal Investigators

  • Shigao D. Chen, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-22
Primary Completion
2027-12-17
Completion
2029-12-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07280312 on ClinicalTrials.gov